Please assess the completion status of the following clinical trial:

Trial Title: Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologically confirmed CLL or SLL requiring therapy~* Age 18 years of age or older~* ECOG performance status 0, 1, or 2~* Normal organ and bone marrow function~* Resolution of toxic effects from prior therapies~* Ability to adhere to the study schedule and give written informed consent~Exclusion Criteria:~* Any serious medical, psychiatric illness or laboratory abnormality~* Chemotherapy or radiotherapy within 4 weeks of entering the study~* Currently receiving other treatment for CLL/SLL or other malignancies~* Active other malignancies~* History of allergic reactions to bendamustine or ofatumumab~* Ongoing corticosteroid use~* Pregnant or lactating~* HIV positive~* Active hepatitis B~* Allogeneic transplant within 6 months of entering study or graft-versus-host disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ofatumumab and Bendamustine (Type: EXPERIMENTAL): Ofatumumab and Bendamustine

Based on this trial design, predict the completion outcome and termination type (if applicable).